Categories: All postsCannabis

Organigram could be the next pot stock with a big alcohol/tobacco/pharma deal: Beacon

Ahead of its fourth quarter results, Beacon Securities analyst Russell Stanley says there is lots of upside in Organigram (Organigram Stock Quote, Chart: TSXV:OGI).

Next week, Organigram is expected to report its Q4, 2018 results. This morning, management announced it had adjourned its AGM until December 17 to allow for its fourth quarter results to be filed.

Stanley says he expects the company to pursue a TSX graduation and possibly a U.S. listing, the latter he thinks might provide a “meaningful catalyst” for the stock. He thinks another, even more meaningful catalyst might come from his assessment that the company might be next in line for the kinds of partnerships that peers Canopy Growth Corp. and Cronos Group have signed with liquor giant Constellation Brands and cigarette maker Altria, respectively.

“With WEED and CRON now ‘spoken for’, the number of attractive-yet-available dance partners for potential strategic investors from the beverage alcohol/tobacco/pharmaceutical industries is beginning to dwindle,” the analyst says. “We view OGI as a member of an elite group of cannabis companies that offer large-scale, low-cost production, demonstrated success in commercializing higher value-added products, and an attractive valuation to boot (OGI trades at 7x our C2020E EBITDA forecast vs. CRON’s 35x consensus, based on last night’s close). We therefore view it as a very attractive candidate for potential strategic investors/acquirors.”

In a research update to clients today, Stanley maintained his “Buy” rating and one-year price target of $11.50 on Organigram, implying a return of 131 per cent at the time of publication.

Stanley thinks OGI will post Adjusted EBITDA of negative $6.3-million on revenue of $13.8-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $35.1-million on a topline of $113.5-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: ogi
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

13 hours ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

15 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

16 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

17 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

4 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

4 days ago